Related Experiment Video
Updated: Sep 28, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.3K
Multimodal Deep Learning Models for Detecting Dementia From Speech and Transcripts
Loukas Ilias1, Dimitris Askounis1
1Decision Support Systems Laboratory, School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece.
Frontiers in Aging Neuroscience
|April 4, 2022
Summary
This study introduces novel multimodal neural network methods for early Alzheimer's dementia (AD) detection and Mini-Mental State Examination (MMSE) score prediction, achieving state-of-the-art results.
Area of Science:
- Neuroscience
- Artificial Intelligence
- Computational Linguistics
Background:
- Alzheimer's dementia (AD) poses significant psychological, social, and economic burdens.
- Early diagnosis of AD is crucial but limited by current multimodal analysis methods.
- Existing approaches often concatenate or average predictions from separate speech and text models.
Purpose of the Study:
- To develop novel end-to-end trainable methods for AD detection and MMSE score prediction.
- To effectively combine speech, transcript, and visual data within a single neural network.
- To overcome limitations of existing multimodal fusion techniques in AD research.
Main Methods:
- Utilized BERT and Vision Transformer for transcript and image processing, respectively.
- Implemented a Co-Attention layer for simultaneous image and word attention.
- Introduced a Multimodal Shifting Gate and a self-attention mechanism with a gate model for inter- and intra-modal interaction.
- Processed audio into Log-Mel spectrograms and their derivatives.
Main Results:
- Achieved 90.00% accuracy in AD classification.
- Attained a Root Mean Squared Error (RMSE) of 3.61 in MMSE regression.
- Demonstrated superior performance compared to existing methods on the ADReSS Challenge dataset.
- Established a new state-of-the-art in MMSE regression.
Conclusions:
- The proposed multimodal fusion methods significantly improve AD detection and MMSE score prediction.
- End-to-end trainable models integrating diverse data modalities offer a promising direction for AD research.
- The developed approach effectively captures complex inter- and intra-modal interactions for enhanced diagnostic accuracy.
Related Concept Videos
Dementia
199
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
199
Alzheimer's Disease: Overview
705
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
705
Alzheimer's Disease: Treatment
274
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
274

